Abstract:BACKGROUND: Osteosarcoma is the most common primary tumor of bone. It is a highly vascular and extremely destructive malignancy that mainly affects children and young adults. The authors conducted microarray-based comparative genomic hybridization (aCGH) and pathway analyses to gain a systemic view of pathway alterations in the genetically altered genes. METHODS: Recurrent amplified and deleted genes that were detected by aCGH were subjected to an analysis based on the Kyoto Encyclopedia of Genes and Genomes to identify the altered pathways. Among the enriched pathways, vascular endothelial growth factor (VEGF) pathway genes collectively were amplified, and alterations of this pathway were validated by fluorescence in situ hybridization (FISH) and immunohistochemistry analyses in 58 formalin-fixed, paraffin-embedded osteosarcoma archival tissues that had clinical follow-up information. RESULTS: The pathway enrichment analyses of the aCGH data revealed that VEGF pathway genes, including the VEGFA gene itself, were amplified significantly in osteosarcoma. Genetic amplification of the VEGFA gene, both focally and in larger fragment, was validated by FISH analysis. It is noteworthy that amplification of the VEGFA gene and elevated expression of the VEGFA protein were associated significantly with microvascular density and adverse tumor-free survival in patients with osteosarcoma. CONCLUSIONS: The authors report for the first time that VEGF pathway genes, including the VEGFA gene, are amplified in osteosarcoma. Amplification of the VEGFA gene is not only an important mechanism for elevated VEGFA protein expression but also is a poor prognostic factor for tumor-free survival. Combined classification of VEGFA gene amplification and positive VEGFA protein expression may provide a more accurate stratification method of selecting anti-VEGF therapy for patients with osteosarcoma. Cancer 2011; 117: 4925-38. (C) 2011 American Cancer Society.

The Role of VE-cadherin in Osteosarcoma Cells

Clinical predictive value of serum angiogenic factor in patients with osteosarcoma.

VEGF-siRNA Silencing Induces Apoptosis, Inhibits Proliferation and Suppresses Vasculogenic Mimicry in Osteosarcoma in Vitro.

Vasculogenic mimicry of osteosarcoma cells

Effects of Vascular Endothelial Growth Factor-Sirna on Apoptosis and Vasculo-Genic Mimicry of Osteosarcoma Cells

Vasculogenic mimicry of cultured osteosarcoma cells in vitro

Inhibitory Effects of VEGF-siRNA Mediated by Adenovirus on Osteosarcoma-Bearing Nude Mice

Expression of Vascular Endothelial Growth Factor （VEGF） in Human Osteosarcoma Cells Transfected with Adeno-associated Virus-antisense VEGF

Vasodilator-stimulated Phosphoprotein Regulates Osteosarcoma Cell Migration.

[Morphological Changes in Osteosarcoma Xenografts in Nude Mice after Inhibiting Angiogenesis by Ad-VEGF-siRNA].

Vasculogenic Mimicry in Osteosarcoma : Histomorphologic Studies in Vivo and in Vitro

Role of extracellular vesicles in osteosarcoma

Vascular Channel Formation by Osteosarcoma Cells in Vitro: Vasculogenic Mimicry

Effects of adenovirus-mediated VEGF-siRNA on the growth of xenografted human osteosarcoma in nude mice

Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study

Expression of survivin and its relationship with vascular endothelial cell growth factor in osteosarcoma

Vasculogenic mimicry: a new prognostic sign of human osteosarcoma.

Inhibition of vascular endothelial growth factor expression in osteosarcoma transfected by Adeno-associated virus gene

MicroRNA-145 Targets Vascular Endothelial Growth Factor and Inhibits Invasion and Metastasis of Osteosarcoma Cells.

Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.

Effect of TSP-1 gene on angiogenesis of osteosarcoma and its mechanism